Other News

Keystone Heart Ltd to Accelerate Trials for Advanced Device to Protect Brain During Heart Procedures

NEWS PROVIDED BY Keystone Heart Ltd.  Aug 01, 2017, 13:06 ET CAESAREA, Israel and TAMPA, Fla., Aug. 1, 2017 /PRNewswire/ — Keystone Heart Ltd., an emerging medical device company focused on developing cerebral protection devices for patients undergoing cardiac procedures, today announced plans to initiate clinical trials for a new, advanced version of Keystone Heart TriGuard™ cerebral […]

Laminate Medical Technologies Receives IDE Approval From FDA To Initiate Clinical Study Of The VasQ Device

TEL AVIV, Israel–(BUSINESS WIRE)–Laminate Medical Technologies (Laminate), an Israeli biomedical start-up developing VasQ, an implanted blood vessel external support device for patients requiring arteriovenous fistula as vascular access for hemodialysis, today announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA). IDE approval […]

LimFlow Announces Publication Of Positive Results From Pilot Study Of Limflow Percutaneous Deep Vein Arterialization (pDVA) System

PARIS–(BUSINESS WIRE)–LimFlow SA today announced publication of positive results from the pilot study of the LimFlow Percutaneous Deep Vein Arterialization System (pDVA) in the July issue of the Journal of Endovascular Therapy. The paper is entitled “Midterm Outcomes from a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option […]

W. L. Gore & Associates Release: GORE VIATORR TIPS Endoprosthesis With Controlled Expansion May Reduce Portal Hypertension Readmissions In Ongoing Study

FLAGSTAFF, Ariz.–(BUSINESS WIRE)–The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion, a new device configuration developed by W. L. Gore & Associates, Inc. (Gore), may further reduce portal hypertension treatment complications, even compared to the GORE® VIATORR® TIPS Endoprosthesis, Gore’s legacy TIPS device, which has a strong history of patency and proven […]

Boston Scientific Nixes Bioresorbable Stent Program

Boston Scientific decides it’s too risky and that there are “bigger” problems to deal with. Boston Scientific to end Renuvia bioresorbable coronary stent program JULY 31, 2017 BY FINK DENSFORD, MassDevice Boston Scientific (NYSE:BSX) is looking to terminate its Renuvia bioresorbable coronary stent program, according to a Minneapolis Star Tribune report. The move comes after […]

CardioFocus® Receives Approval For HeartLight® Endoscopic Ablation System From The Japanese Ministry Of Health, Labour And Welfare

MARLBOROUGH, Mass., July 31, 2017 /PRNewswire/ — CardioFocus, Inc. today announced that the Japanese Ministry of Health, Labour and Welfare has approved the HeartLight Endoscopic Ablation System for the treatment of paroxysmal atrial fibrillation (AF) in Japan. The HeartLight System is a visually guided laser balloon technology for controlled and consistent pulmonary vein isolation (PVI) […]

Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing

DUBLIN – July 31, 2017 – Medtronic plc (NYSE:MDT) today announced CE (Conformité Européenne) mark and European launch of the CoreValve(TM)Evolut(TM) PRO valve for the treatment of severe aortic stenosis for symptomatic patients who are at intermediate, high or extreme risk for open heart surgery. Clinical data for the Evolut PRO valve […]

Cardinal Health Completes Acquisition of Medtronic’s Patient Recovery Business

DUBLIN, Ohio, July 30, 2017 /PRNewswire/ — Cardinal Health (NYSE: CAH) today announced that it has completed the acquisition of Medtronic’s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business for $6.1 billion. The acquisition was funded with a combination of $4.5 billion in new senior unsecured notes, existing cash and borrowings under our existing credit […]

QT Vascular begins enrollment in US pivotal study of its drug-coated peripheral balloon

SINGAPORE, July 31, 2017 /PRNewswire/ — QT Vascular Ltd., together with its subsidiaries (the “Company”), announced it has started enrollment in its United States (“US“) pivotal clinical study. The study will evaluate the Company’s drug coated balloon (“DCB“), the Chocolate Touch®, for use in superficial femoral and popliteal arteries with the intention of obtaining […]